Plasma Medicine against Actinic Keratosis

The quality of human (and veterinary) health care systems substantially depends on key innovations.

Often, these were driven by the field of physics, followed by interdisciplinary and inter-sectorial actions in engineering, chemistry, biology, and medicine, such as X-rays in medical diagnostics, ionizing radiation in cancer treatment, and femtosecond lasers for precision surgery. Medical gas plasma technology was introduced to human health care a decade ago.

Today, accredited medical plasma devices are in daily operation in dozen dermatology centers in middle Europe to improve wound healing. In addition, physical plasmas were shown to inactivate cancerous cells.

Actinic Keratosis is a skin disease affecting millions of Europeans and making them prone to invasive and deadly skin cancer. Many of the available treatment options are associated with low efficacy, pain, risks, and/or high costs.

Medical gas plasma technology is operated at body temperature and applied painlessly, cost-effectively, and without notable side effects.

Gas plasma has been suggested to be active on high-grade cancer cells, but its activity against premalignant cells, as in Actinic Keratosis, is unknown.

By using beyond state-of-the-art plasma multijet technology, the primary technical objective of PlasmACT Plasma against Actinic Keratosis is to support skin cancer prevention by medical gas plasma therapy of Actinic Keratosis.

PlasmACT does so by educating a new generation of application-oriented scientists that are exposed to questions and findings from different scientific fields (interdisciplinary from physics over chemistry and biology to medicine) and capable of addressing questions in view of both academic as well as business needs (inter-sectoral) while incorporated in a vivid and productive environment across borders and cultures (international).